Australian Clinical Labs 과거 수익 실적

과거 기준 확인 4/6

Australian Clinical Labs의 수입은 연평균 -24%의 비율로 감소해 온 반면, Healthcare 산업은 수입이 연평균 19%의 비율로 감소했습니다. 매출은 연평균 11.7%의 비율로 감소해 왔습니다. Australian Clinical Labs의 자기자본이익률은 18.3%이고 순이익률은 4.2%입니다.

주요 정보

-24.0%

수익 성장률

-27.8%

EPS 성장률

Healthcare 산업 성장	2.4%
매출 성장률	-11.7%
자기자본 수익률	18.3%
순이익	4.2%
다음 실적 업데이트	26 Aug 2025

최근 과거 실적 업데이트

Recent updates

Australian Clinical Labs Limited Just Missed Earnings - But Analysts Have Updated Their Models

Mar 02

Operational Improvements And New Genomic Tests Aim To Improve Future Outlook

Feb 09 Improving collection centers and digital transformations are set to enhance operational efficiency, boosting profit margins and supporting revenue growth.

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

수익 및 비용 분석

Australian Clinical Labs 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

ASX:ACL 수익, 비용 및 수입 (AUD Millions )
날짜	수익	수익	G+A 비용
31 Dec 24	728	31	0
30 Sep 24	712	27	0
30 Jun 24	696	24	0
31 Mar 24	685	20	0
31 Dec 23	674	15	0
30 Sep 23	686	26	0
30 Jun 23	697	36	0
31 Mar 23	757	55	0
31 Dec 22	818	73	0
30 Sep 22	907	126	0
30 Jun 22	996	178	0
31 Mar 22	931	156	0
31 Dec 21	867	134	0
30 Sep 21	757	97	0
30 Jun 21	647	60	0
31 Mar 21	598	79	0
31 Dec 20	549	98	0
30 Sep 20	520	70	0
30 Jun 20	491	41	0
30 Jun 19	448	-11	315
30 Jun 18	379	-9	267
30 Jun 17	340	-24	252

양질의 수익: ACL 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: ACL 의 현재 순이익 이익률 (4.2%) 작년보다 높습니다 (2.3%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: ACL 의 수입은 지난 5년 동안 매년 24% 씩 감소했습니다.

성장 가속화: 지난 1년간 ACL 의 수익 증가율( 98.7% )은 연간 평균( -24% 초과합니다. ).

수익 대 산업: 지난 1년간 ACL 수익 증가율( 98.7% )은 Healthcare 업계 8% 초과했습니다.

자기자본 수익률

높은 ROE: ACL 의 자본 수익률( 18.3% )은 낮음으로 간주됩니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/03 20:00
장 마감 주가	2025/05/02 00:00
수익	2024/12/31
연간 수익	2024/06/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Australian Clinical Labs Limited 11 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Lyanne Harrison	BofA Global Research
Mathieu Chevrier	Citigroup Inc
Gretel Janu	Credit Suisse

Australian Clinical Labs 과거 수익 실적

과거 기준 확인 4/6

주요 정보

최근 과거 실적 업데이트

First half 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Recent updates

Upcoming dividend of AU$0.035 per share

Investor sentiment deteriorates as stock falls 16%

Australian Clinical Labs Limited Just Missed Earnings - But Analysts Have Updated Their Models

First half dividend increased to AU$0.035

First half 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Confirms Earnings Guidance for the Year 2025

Operational Improvements And New Genomic Tests Aim To Improve Future Outlook

Less than half of directors are independent

Australian Clinical Labs Limited Appoints Sarah Butler and Grant Jeffery as Non-Executive Directors, Effective 1 February 2025

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

수익 및 비용 분석

수익 및 매출 내역